Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX), with its substantial $114.5 billion market capitalization, continues to dominate the cystic fibrosis (CF) treatment market while advancing a ...

Vertex built its business treating the underlying genetic cause of cystic fibrosis (CF), a rare ... One is from a phase 1/2 study evaluating VX-522, a messenger RNA therapy that could treat ...

Detailed price information for Vertex Pharmaceutic (VRTX-Q) from The Globe and Mail including charting and trades.

Vertex built its business treating the underlying genetic cause of cystic fibrosis (CF), a rare disease that affects only around 109,000 patients worldwide. Suzetrigine could open the door to a ...

According to InvestingPro analysis, the company stands as a prominent player in the Biotechnology industry, with a strong focus on cystic fibrosis (CF ... particularly the development of suzetrigine ...

We now have five approved medicines in cystic fibrosis ... data releases that we expect to share this year. The first is VX-522, our mRNA program in partnership with Moderna for the last 10% ...

APOL1-Mediated Kidney Disease (AMKD) – Inaxaplin (VX-147) Vertex continues to enroll and dose patients ... life-shortening genetic diseases — cystic fibrosis, sickle cell disease and ...

Vertex Pharmaceuticals Incorporated today announced multiple program updates ahead of upcoming investor meetings in January, including the company's scheduled webcast from the 43rd Annual J.P. Morgan ...

The company has approved medicines that treat the underlying causes of multiple chronic, life-shortening genetic diseases — cystic fibrosis, sickle cell disease and transfusion-dependent beta ...

VX-522: The multiple ascending dose (MAD ... Vertex increased its estimates for the number of people with cystic fibrosis in the U.S., Europe, Australia, and Canada from approximately 92,000 ...

VX-522: The multiple ascending dose (MAD ... Epidemiology and market opportunity update: Vertex increased its estimates for the number of people with cystic fibrosis in the U.S., Europe, Australia, ...